Telomerase Reverse Transcriptase Gene Delivery via Non-Integrating AAV Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for treating diseases associated with shortened telomeres, such as aplastic anemia, Dyskeratosis congenita, and Myelodysplastic Syndrome, as they fail to effectively address the underlying issue of telomere shortening and its consequences on tissue regeneration and longevity.
Innovation Solution
A nucleic acid vector comprising a coding sequence for telomerase reverse transcriptase (TERT) is administered to subjects with shortened telomeres, using an adeno-associated virus-based non-integrative vector to activate telomerase expression, thereby extending telomere length and delaying tissue degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat diseases associated with shortened telomeres, then treatment is provided, but the underlying issue of telomere shortening is not effectively addressed
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediaries to deliver the TERT gene into target cells. The AAV vector acts as a mediator that safely transports the telomerase reverse transcriptase coding sequence into cells, enabling telomere length extension without direct injection of complex proteins or enzymes. This intermediary approach resolves the contradiction by providing reliable gene delivery that effectively addresses telomere shortening while maintaining safety.
Solution Approach 2:
The patent introduces the TERT coding sequence into cells before the actual telomere extension is needed. By preliminarily establishing the genetic capability to produce telomerase reverse transcriptase, the system prepares cells to autonomously extend their telomeres when activated. This preliminary genetic modification ensures that when the therapy is administered, the cells can immediately begin addressing telomere shortening without requiring complex external delivery mechanisms.
2Duration of action of stationary object
If telomerase is activated to extend telomere length, then tissue degeneration is delayed, but there may be risks of uncontrolled cell proliferation
Solution Approach 1:
The patent employs tissue-specific promoters to drive TERT expression only in specific cell types and tissues that require telomere maintenance. Rather than constitutively expressing telomerase throughout the body, the system activates telomerase locally in target tissues such as muscle, liver, or neural tissues. This local quality approach extends tissue longevity in specific organs while minimizing the risk of uncontrolled proliferation in other tissues, effectively resolving the contradiction between tissue longevity and cancer risk.
Solution Approach 2:
The patent uses inducible or regulated promoter systems that allow control over the level and timing of TERT expression. By changing the parameters of gene expression (when, where, and how much telomerase is produced), the system can extend telomeres in a controlled manner. This parameter control enables delayed tissue degeneration while preventing uncontrolled cell proliferation by adjusting expression levels to physiological ranges rather than constitutive high-level expression.
3Productivity
If a viral vector is used to deliver the TERT gene, then gene delivery efficiency is improved, but concerns about integration and mutagenesis arise
Solution Approach 1:
The patent uses adeno-associated virus (AAV) as an intermediary vector system that offers both high delivery efficiency and improved safety compared to integrating viral vectors. AAV vectors can efficiently deliver the TERT coding sequence into target cells while generally remaining episomal rather than integrating into the host genome. This intermediary approach resolves the contradiction by providing productive gene delivery without the mutagenic risks associated with random integration, as AAV genomes typically persist as extrachromosomal elements.
Solution Approach 2:
The patent employs non-integrating AAV vector systems that replicate and deliver genetic material without permanently altering the host genome. The TERT coding sequence is delivered as a temporary copy that can be expressed transiently or semi-permanently without becoming part of the chromosomal DNA. This copying mechanism maintains high gene delivery efficiency while eliminating the risks of insertional mutagenesis, as the delivered genetic material does not integrate into host chromosomes and cannot cause genomic disruptions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment significantly increases telomere length, delays bone marrow failure, and extends lifespan in affected subjects, improving overall fitness and reducing the incidence of associated diseases.
Implementation Method 1
using an adeno-associated virus-based non-integrative vector to activate telomerase expression
Implementation Method 2
Telomerase is a cellular reverse transcriptase (TERT, telomerase reverse transcriptase; also known as TP2; TRT; EST2; TCSI; hEST2) capable of compensating telomere attrition through de novo addition of TTAGGG repeats onto the chromosome ends by using an associated RA component as template (Terc, telomerase RNA component)
Data Source
Figure 1A~1E
Figure 2A~2E
AI summary
The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.